$553 Million is the total value of Aquilo Capital Management, LLC's 17 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 23.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SPY | New | SPDR S&P 500 ETF TRput | $118,899,000 | – | 300,000 | +100.0% | 21.49% | – |
| XBI | SPDR S&P BIOTECH ETF TRput | $67,825,000 | -3.7% | 500,000 | 0.0% | 12.26% | -16.2% | |
| SPRO | Sell | SPERO THERAPEUTICS INC | $56,366,000 | -26.1% | 3,829,209 | -2.6% | 10.19% | -35.7% |
| DRNA | Buy | DICERNA PHARMACEUTICALS INC | $43,607,000 | +46.0% | 1,705,392 | +25.8% | 7.88% | +27.0% |
| BPMC | Buy | BLUEPRINT MEDICINES CORP | $41,129,000 | -3.5% | 423,012 | +11.3% | 7.43% | -16.1% |
| NGM | Buy | NGM BIOPHARMACEUTICALS INC | $32,682,000 | +7.3% | 1,124,237 | +11.8% | 5.91% | -6.7% |
| HARP | New | HARPOON THERAPEUTICS INC | $32,514,000 | – | 1,554,199 | +100.0% | 5.88% | – |
| QURE | Buy | UNIQURE NV | $32,188,000 | +26.9% | 955,424 | +36.1% | 5.82% | +10.3% |
| MGTA | Buy | MAGENTA THERAPEUTICS INC | $29,626,000 | +66.7% | 2,502,210 | +10.4% | 5.35% | +45.0% |
| ARWR | Buy | ARROWHEAD PHARMACEUTICALS IN | $27,050,000 | -3.7% | 407,926 | +11.5% | 4.89% | -16.2% |
| RGNX | Buy | REGENXBIO INC | $19,083,000 | -16.4% | 559,444 | +11.1% | 3.45% | -27.3% |
| FDMT | Buy | 4D MOLECULAR THERAPEUTICS IN | $13,052,000 | +1474.4% | 300,886 | +1404.4% | 2.36% | +1271.5% |
| AMYT | AMRYT PHARMA PLCsponsored ads | $11,144,000 | -1.6% | 800,000 | 0.0% | 2.01% | -14.4% | |
| PIRS | PIERIS PHARMACEUTICALS INC | $9,446,000 | +2.8% | 3,675,530 | 0.0% | 1.71% | -10.6% | |
| GLPG | Buy | GALAPAGOS NVspon adr | $8,998,000 | +29.9% | 116,723 | +66.8% | 1.63% | +12.9% |
| ARGX | Buy | ARGENX SEsponsored adr | $5,838,000 | +56.3% | 21,200 | +66.9% | 1.06% | +36.0% |
| GMAB | Buy | GENMAB A/Ssponsored ads | $3,940,000 | +7.7% | 120,000 | +33.3% | 0.71% | -6.3% |
| ANAB | Exit | ANAPTYSBIO INC | $0 | – | -1,215,958 | -100.0% | -5.43% | – |
| IBB | Exit | ISHARES TRput | $0 | – | -500,000 | -100.0% | -15.74% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-17
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| PIERIS PHARMACEUTICALS INC | 20 | Q3 2023 | 7.1% |
| ARROWHEAD PHARMACEUTICALS INC | 18 | Q3 2023 | 22.1% |
| UNIQURE NV | 18 | Q1 2023 | 10.8% |
| SPERO THERAPEUTICS INC | 16 | Q3 2022 | 15.8% |
| REGENXBIO INC | 16 | Q3 2023 | 12.6% |
| BLUEPRINT MEDICINES CORP | 15 | Q3 2023 | 17.3% |
| ARGENX SE | 15 | Q3 2023 | 3.7% |
| SPDR S&P BIOTECH ETF TR | 14 | Q4 2022 | 52.1% |
| MERUS N V | 14 | Q3 2023 | 13.0% |
| GENMAB A/S | 13 | Q3 2023 | 3.9% |
View Aquilo Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Spero Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Merus N.V. | February 14, 2020 | 814,505 | 2.8% |
| SYNLOGIC, INC.Sold out | February 14, 2020 | 0 | 0.0% |
View Aquilo Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-03-18 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
View Aquilo Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.